Home   >  
∨

Classified by application

All Products

Signaling Pathways

Research Areas

Nature products

Antibodies

Peptides

Catalysts

Impurities

Intermediate

Raw Materials

MAPK Pathway

Chemical Structure Cat. No. Product Name CAS No.
MK-2 Inhibitor III H2O Chemical Structure
 BCP44458 MK-2 Inhibitor III H2O 1186648-22-5
MK2-IN-3 hydrate is an orally active, selective, and ATP-competitive MAPKAP-K2 (MK-2) inhibitor with an IC50 of 0.85 nM.
Encorafenib Chemical Structure
 BCP44104 Encorafenib 1269440-29-0
Encorafenib is an orally available Raf kinase inhibitor with potential antineoplastic activity. LGX818 specifically inhibits Raf kinase, a serine/threonine enzyme in the RAF/mitogen-activated protein kinase kinase (MEK)/extracellular signal-related kinase (ERK) signaling pathway. By inhibiting the activation of the RAF/MEK/ERK signaling pathway, the administration of LGX818 may result in a decrease in proliferation of tumor cells.
Rineterkib hydrochloride Chemical Structure
 BCP43938 Rineterkib hydrochloride 1715025-34-5
Rineterkib is a RAF and ERK1/2 inhibitor which has demonstrated preclinical activity in multiple MAPK activated cancer cells and xenograft models.
Indirubin-3'-oxime Chemical Structure
 BCP43705 Indirubin-3'-oxime 667463-82-3
Indirubin-3'-monoxime, a synthetic derivative of indirubin, is a potent inhibitor of cyclin-dependent kinases (CDKs) and glycogen synthase kinase 3β (GSK3β). Indirubin-3′-oxime directly inhibits the activity of all three isoforms of JNK (JNK1, JNK2, and JNK3), with IC50s of 0.8 μM, 1.4 μM, and 1.0 μM, respectively. Indirubin-3′-oxime can enhance height growth via activation of Wnt/β-catenin signaling in chondrocytes.
MCP110 Chemical Structure
 BCP43521 MCP110 521310-51-0
MCP110 is an inhibitor of Ras.
HPK1-IN-7 Chemical Structure
 BCP43399 HPK1-IN-7 2320462-65-3
HPK1-IN-7 is a potent, orally active HPK1 inhibitor.
Vemurafenib Chemical Structure
 BCP43160 Vemurafenib 1029872-54-5
Vemurafenib is a selective inhibitor of BRAF kinase that is used in the therapy of patients with metastatic and advanced malignant melanoma. Vemurafenib therapy is commonly associated with transient elevations in serum aminotransferase during therapy and has been linked to rare, but occasionally severe cases of clinically apparent acute liver injury.
Lifirafenib Chemical Structure
 BCP42783 Lifirafenib 1446090-79-4
Lifirafenib is a Novel potent and selective RAF Kinase and EGFR inhibitor.
MK2 Inhibitor III Chemical Structure
 BCP41255 MK2 Inhibitor III 724711-21-1
MK2 Inhibitor III is a potent, cell-permeable inhibitor of mitogen-activated protein kinase-activated protein kinase 2 (MAPKAP-K2 or MK-2) and can be used for the treatment of rheumatoid arthritis.
PF 3644022 Chemical Structure
 BCP40723 PF 3644022 1276121-88-0
PF 3644022 is a potent freely reversible ATP-competitive compound that inhibits MK2 activity (IC50 = 5.2 nM; Ki = 3 nM) with good selectivity when profiled against 200 human kinases.
123下一页末页共 233 条记录 1 / 24 页 
0086-15971444841